NovoCure (NVCR) Free Cash Flow (2014 - 2026)

NovoCure has disclosed Free Cash Flow across 13 years of filings, most recently posting -$18.7 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$18.7 million, up 59.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$48.1 million (up 33.36% YoY), and the FY2025 annual result was -$75.7 million, down 9.32% from the prior year.
• Free Cash Flow came in at -$18.7 million for Q1 2026 at NovoCure, up from -$22.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $16.7 million in Q3 2022 to a low of -$46.3 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$18.7 million (2026), against an average of -$15.0 million.
• Across the five-year window, Free Cash Flow tumbled 7898.46% in 2022 and jumped 4959.61% in 2025, its largest moves.
• NovoCure's Free Cash Flow stood at -$10.1 million in 2022, then plunged by 110.88% to -$21.4 million in 2023, then soared by 42.03% to -$12.4 million in 2024, then plunged by 84.78% to -$22.9 million in 2025, then grew by 18.48% to -$18.7 million in 2026.
• The last three Free Cash Flow figures came in at -$18.7 million (Q1 2026), -$22.9 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.